The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fretblanket - totally agree.
I think the RNS was worded very badly.... if you hear what he has to say, sounded very bullish... really surprised of the hard sell. I can see this bounce back very aggressively once people truly understand the study now has been accelerated further. You don't do that, if you think the product will fail.
as always GLA
3,The pre In Vivo study failed and Nuvec doesn’t work.
Now listen to the Directors Talk interview on the 14th September
Main points being:
The Covid project is to show proof of concept to show Nuvec’s versatility.
The plasma for covid is a low expresser so it is quite difficult to pick the protein up in a one injection study, including the control.
They could have spent a lot more time trying to detect the protein but as they now have the funds to do so they have moved straight onto the In Vivo study
So my view, as with a few on here, is there was no reason for the big drop in the share price. If anything it should have increased as they have accelerated the project and it is going the right direction.
The RNS was not the clearest and having now had the time to do the above research I am as confident as I was before that this study will be positive. Let’s hope it is otherwise no doubt we will see another big drop in the share price even though this is only one part of the work they are currently doing.
Now off to listen to this https://www.***************************/n4-pharma-in-very-good-shape-as-it-moves-forward-interview/412859314 which has just be uploaded!
1/2
Just some musings on the covid project.
From the RNS dated 16th April
Stage one (amplification of the plasmid DNA) - Starting in May, time to take fours weeks
Stage two (In Vitro) Starting in Jun, time to take 10 weeks.
Stage 3. subject to positive results being achieved at stage 2, undertaking an initial Pre In Vivo study. Starting mid-July, time to take ten weeks,
Once the stage 3 results have been reviewed, the Company will then determine whether to do a further In Vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies.
From RNS dated 28th May
Stage One completed successfully move on to stage Two. All on schedule
‘Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.’
From RNS 6th July
Despite Covid-19 all on track with Covid project. Again highlighted that the company ‘continues to look at ways in which it can accelerate the commencement of Stage 3 of the Covid-19 work (as set out in the Company's announcement on 16 April 2020) and perform the in vivo protein expression’
From RNS August 12th
Stage two has worked. Moving onto stage 3 Pre In Vivo study
Nigel is quoted as saying ‘We now move straight to the third stage of our Covid-19 project with our pre in vivo study at Evotec. The global pandemic continues to dominate all of our lives and we are extremely excited to be moving onto the next stage of our Covid-19 project, the successful outcome of which will determine our next work streams in this area and how we might collaborate with appropriate partners interested in any advantage our Nuvec® delivery system may provide’
‘We now move straight to the third stage of our Covid-19 project with our pre in vivo study at Evotec’ he did not say we continue with. Remember they said that wanted to try and run stage 3 alongside stage 2. This certainly could give the impression they had not started stage 3.
From RNS 14th September
Stage 3 ‘did not result in a measurable expression of the spike protein in the target cells of the murine target.’
‘The initial pilot work of stage 3 of the Covid-19 proof of concept work was narrow in its scope’
’the Company has decided to proceed to a full in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies’
If stage 3 had not started until the end of stage two(12th August) and it takes 10 weeks to run(stated in RNS 16th April) why did we get the results only 4 ½ weeks later (Sept 14th)??
Potential answers;
1, They were so happy with stage 2 results( and Nuvec in general) they did a very quick stage 3 with proof being ‘The initial pilot work of stage 3 of the Covid-19 proof of concept work was narrow in its scope’
2, They started before the end of stage 2, which in fairness they had hoped but no clear indication th